Bio Materials
Daejeon Bio R&D Center: bio material research by microbial fermentation and enzymatic conversion
Building on microbial fermentation and enzymatic conversion technologies,
Ace Biopharm researches and develops bio ingredients.
Daejeon Bio R&D Center
We established our Corporate R&D Center in 2018 and opened the Daejeon Bio R&D Center in 2019.
Our research team, composed of M.S. and Ph.D.-level researchers, conducts study through three specialized teams focusing on 1) microbial cultivation, 2) purification processes, and 3) product development.
Functional food ingredients developed through our R&D efforts are exported to the United States and Japan.
Three Platform Technologies
Advanced cultivation and purification systems
We establish competitive production process through industrial strains improvement and optimization of fermentation and purification.
Eco-friendly Production Processes
We replace chemical processes with enzymatic conversion.
Digital twin technology
We develop predictive models for bioprocess scale-up.
R&D Pipeline
Vitamin K2 (Menaquinone-7)
A health functional food ingredient that may help support bone and vascular health.
In mass production · exported under long-term contracts since 2025 · 4 production technology patents
UDCA (Ursodeoxycholic Acid)
An active pharmaceutical ingredient for liver disease, made by enzymatic bioconversion instead of a chemical process.
National R&D project completed (2024) · 2 domestic patents · 2 overseas patents · 2 PCT applications
L-theanine
An individually approved health functional food ingredient used for relaxation and immune activity.
National R&D project completed (2025) · animal testing and bioactivity testing completed
Probiotics
A functional material that may help with hangover relief and immune function.
Health functional food OEM sales underway
Sphinganine
A ceramide-family cosmetic ingredient used for moisturizing and skin protection.
Process scale-up completed · contract manufacturing agreement signed · national R&D project underway (to 2027)
Key Research Achievements
| Year | Details |
|---|---|
| 2026 |
|
| 2023 |
|
| 2022 |
|
| 2021 |
|
| 2020 |
|
| 2019 |
|
| 2018 |
|
| 2017 |
|
| 2015 |
|
| 2010 |
|
Patents
| Status | Title | Number |
|---|---|---|
| Registered | Method for producing vitamin K2 from a Bacillus subtilis strain using pH-stat fed-batch culture | 제10-1875502호 |
| Registered | Novel Bacillus subtilis strain BS4 with enhanced menaquinone-7 productivity and method for mass production of menaquinone-7 using the same | 제10-1884659호 |
| Registered | Novel Bacillus subtilis strain BSM-K02 with enhanced menaquinone-7 productivity and method for mass production of menaquinone-7 using the same | 제10-1888072호 |
| Registered | High-efficiency method for purifying menaquinone-7 | 제10-2173340호 |
| Registered | Recombinant vector for enhancing the conversion rate of chenodeoxycholic acid to ursodeoxycholic acid, and method for producing ursodeoxycholic acid using the same | 제10-2802490호 |
| Registered | Variant of 7-beta-HSDH derived from a Ruminococcus gnavus strain for enhancing the conversion rate of 7-keto-LCA to ursodeoxycholic acid, and method for producing ursodeoxycholic acid using the same (PCT application) | No. 10-2747996 · No. 7656964 (registered in Japan) |
| Registered | Oral tablet containing fenofibric acid and method for preparing the samePatentee: Ace Biopharm Co., Ltd., Yonsei University Industry-Academic Cooperation Foundation | 제10-2501636호 |
| Filed | Method for producing ursodeoxycholic acid in a single-vessel reaction using a 7-beta-HSDH variant and 7-alpha-HSDH | 제10-2022-0143108호 |
| Filed | Method for producing ursodeoxycholic acid at high concentration and high efficiency using glycerol (PCT application) | 제10-2023-0152746호 |
| Filed | Recombinant strain and method for producing theanine using the same | 제10-2023-0169659호 |
| Filed | Bacillus mutant strain with high gamma-glutamyl transpeptidase activity and use thereof | 제10-2025-0214985호 |